Barinthus Biotherapeutics Presents Updated Data From Two Clinical Trials In Chronic Hepatitis B At EASL Congress 2024
Barinthus Biotherapeutics Presents Updated Data From Two Clinical Trials In Chronic Hepatitis B At EASL Congress 2024
Barinthus生物医药公司在2024年EASL国际肝病大会上公布了两项慢性乙型肝炎临床试验的最新数据。
- In the HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation.
- In the IM-PROVE II trial, conducted in partnership with Arbutus Biopharma, a statistically significant difference was observed in HBsAg levels between the VTP-300 treatment and placebo groups at 24-weeks post-end of treatment (EOT) and 84% of participants who received VTP-300 discontinued standard of care (SoC) NUC therapy vs 53% receiving placebo.
- 在HBV003试验中，67%的参与者的HBsAg水平小于10 IU/mL，19%的参与者在NUC停药评估（治疗结束或之后）时HBsAg不可检测，76%的参与者符合核苷（酸）类似物（NUC）治疗停药标准。
- 在与arbutus biopharma合作进行的IM-PROVE II试验中，在治疗结束后24周，VTP-300治疗组与安慰剂组之间的HBsAg水平存在统计学差异。治疗结束后（EOT），接受VTP-300治疗的84%的参与者停止了标准板NUC治疗，而接受安慰剂的53%的参与者停止了NUC治疗。接受标准板NUC治疗的53%的参与者停止了NUC治疗，而接受安慰剂的84%的参与者停止了VTP-300治疗。